clomiPRAMINE Hydrochloride Capsules USP — Class II drug recall D-0104-2021
Terminated recall by Jubilant Cadista Pharmaceuticals, Inc., reported 2020-12-02, distributed nationwide. Failed Tablet/Capsule Specification
| Recall number | D-0104-2021 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD, United States |
| Recall initiated | 2020-11-06 |
| Classified | 2020-11-24 |
| Reported by FDA | 2020-12-02 |
| Terminated | 2022-03-23 |
| Distributed | Nationwide (US) |
| Quantity | 4,416 bottles |
| NDC | 59746-0711-30 |
| Lot numbers | 20P0141 |
| Expiration dates | 2022-02 |
Product
clomiPRAMINE Hydrochloride Capsules USP, 50 mg, 30-count bottle, Rx Only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD NDC 59746-711-30
Reason for recall
Failed Tablet/Capsule Specification
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0104-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.